Contact
searchSearch
HMP Global
Login

Bipolar Disorders Topic Center

Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
Delusion Themes Stay Consistent Across Psychosis Episodes
News
Delusion Themes Stay Consistent Across Psychosis Episodes, Study Finds
08/20/2024
Jolynn Tumolo
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar...
08/20/2024
Psych Congress Network
fda
News
FDA Approves Iloperidone for Acute Treatment of Bipolar I Disorder
04/08/2024
Meagan Thistle
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for...
04/08/2024
Psych Congress Network
Patients With First-Episode Psychosis Found to Have Cognitive Impairment Before Medication Use
News
Patients With First-Episode Psychosis Found to Have Cognitive Impairment Before Medication Use
03/26/2024
Evi Arthur
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode...
03/26/2024
Psych Congress Network
Young Adults Who Self-Harm May Be More at Risk of Psychosis Diagnosis
News
Young Adults Who Self-Harm May Be More at Risk of Psychosis Diagnosis
02/27/2024
Evi Arthur
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who...
02/27/2024
Psych Congress Network
Death risk increased by how much with a bipolar disorder diagnosis?
Quiz
Death risk increased by how much with a bipolar disorder diagnosis?
02/26/2024
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/26/2024
Psych Congress Network
Bipolar Disorder Increases Mortality Risk More Than Smoking
News
Bipolar Disorder Increases Mortality Risk More Than Smoking
02/05/2024
Jolynn Tumolo
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.  
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.  
A diagnosis of bipolar disorder...
02/05/2024
Psych Congress Network
Brain with puzzle piece missing
News
Vitamin B6 Plus Lithium Helps Ease Mania Symptoms in Patients With Bipolar Disorder
01/03/2024
Jolynn Tumolo
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive...
01/03/2024
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
bipolar disorder graphic
News
Metformin Helps Prevent Weight Gain in Youth Taking Medication for Bipolar Disorder
11/15/2023
Jolynn Tumolo
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug...
11/15/2023
Psych Congress Network
News
FDA Approves ABILIFY ASIMTUFII for Schizophrenia and Bipolar Disorder Treatment
04/28/2023
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder. 
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder. 
The FDA approved ABILIFY...
04/28/2023
Psych Congress Network

News

Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
Delusion Themes Stay Consistent Across Psychosis Episodes
News
Delusion Themes Stay Consistent Across Psychosis Episodes, Study Finds
08/20/2024
Jolynn Tumolo
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar across episodes of psychosis in patients who relapsed over a 2-year naturalistic course of care, according to a study published in JAMA Psychiatry. 
Delusion content was similar...
08/20/2024
Psych Congress Network
fda
News
FDA Approves Iloperidone for Acute Treatment of Bipolar I Disorder
04/08/2024
Meagan Thistle
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for acute schizophrenia treatment, received FDA approval on Friday for acute treatment of manic or mixed episodes associated with bipolar I in adults.
Ilperidone, already approved for...
04/08/2024
Psych Congress Network
Patients With First-Episode Psychosis Found to Have Cognitive Impairment Before Medication Use
News
Patients With First-Episode Psychosis Found to Have Cognitive Impairment Before Medication Use
03/26/2024
Evi Arthur
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode psychosis (FEP) were found to have cognitive impairment prior to their first use of antipsychotic medications, particularly with large effect sizes, according to recent meta-analysis results published in JAMA...
Patients with first-episode...
03/26/2024
Psych Congress Network
Young Adults Who Self-Harm May Be More at Risk of Psychosis Diagnosis
News
Young Adults Who Self-Harm May Be More at Risk of Psychosis Diagnosis
02/27/2024
Evi Arthur
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who presented to the hospital with self-harm were found to be more likely to receive a psychotic disorder diagnosis later in life, according to recent findings from a cohort study published in the journal...
Young adults and teenagers who...
02/27/2024
Psych Congress Network
Bipolar Disorder Increases Mortality Risk More Than Smoking
News
Bipolar Disorder Increases Mortality Risk More Than Smoking
02/05/2024
Jolynn Tumolo
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.  
A diagnosis of bipolar disorder increased the risk of premature death more than smoking or being older than 60 years, according to study results published in Psychiatry Research.  
A diagnosis of bipolar disorder...
02/05/2024
Psych Congress Network
Brain with puzzle piece missing
News
Vitamin B6 Plus Lithium Helps Ease Mania Symptoms in Patients With Bipolar Disorder
01/03/2024
Jolynn Tumolo
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive therapy to lithium was associated with the improvement of mood symptoms in hospitalized patients with bipolar disorder experiencing a manic episode.
Daily vitamin B6 as adjunctive...
01/03/2024
Psych Congress Network
News
Use of Psilocbyin in Bipolar II Treatment Clinical Trial Produces Strong Results
12/12/2023
Tom Valentino
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by Sheppard Pratt researchers, 80% of participants with treatment-resistant bipolar II met the criteria for remission 12 weeks after treatment that included psilocybin and therapy.
In a recent trial conducted by...
12/12/2023
Psych Congress Network
bipolar disorder graphic
News
Metformin Helps Prevent Weight Gain in Youth Taking Medication for Bipolar Disorder
11/15/2023
Jolynn Tumolo
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug metformin can help prevent, and in some cases reverse, weight gain in youth taking second-generation antipsychotics (SGAs) for BD, according to short-term data from a large-scale trial.
The type 2 diabetes drug...
11/15/2023
Psych Congress Network
News
FDA Approves ABILIFY ASIMTUFII for Schizophrenia and Bipolar Disorder Treatment
04/28/2023
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder. 
The FDA approved ABILIFY ASIMTUFII (aripiprazole), a long-acting injectable (LAI) medication for the treatment of schizophrenia and bipolar I disorder. 
The FDA approved ABILIFY...
04/28/2023
Psych Congress Network
Study on MDD - stock image
News
Phase II Trial of AL001 for MDD Set to Begin Later this Year
03/24/2025
Jolynn Tumolo
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a...
03/24/2025
Psych Congress Network
US FDA sign
News
FDA Seeks Clearer Labeling for Transmucosal Buprenorphine Product Dosing
03/24/2025
Jolynn Tumolo
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that...
03/24/2025
Psych Congress Network
3 medical professionals stand together talking in the hallway of a medical facility
News
Accelerated Theta-Burst Stimulation Protocol Improves Treatment-Resistant Depression
03/21/2025
Jolynn Tumolo
A novel 78-minute accelerated theta-burst stimulation (aTBS) protocol reduced depression severity in patients with treatment-resistant depression (TRD), according to results from a randomized clinical trial published in JAMA Psychiatry.
A novel 78-minute accelerated theta-burst stimulation (aTBS) protocol reduced depression severity in patients with treatment-resistant depression (TRD), according to results from a randomized clinical trial published in JAMA Psychiatry.
A novel 78-minute accelerated...
03/21/2025
Psych Congress Network
an older man wearing glasses rubs his face in stress tired depression treatment resistant depression
News
Genetic Predispositions to Insomnia, Neuroticism, Linked With Higher Risk for Treatment-Resistant Depression
03/18/2025
Jolynn Tumolo
A genetic predisposition to traits including neuroticism, cognitive function, and sleep patterns were significantly associated with the development of treatment-resistant depression (TRD) in a cohort study published in JAMA Psychiatry.
A genetic predisposition to traits including neuroticism, cognitive function, and sleep patterns were significantly associated with the development of treatment-resistant depression (TRD) in a cohort study published in JAMA Psychiatry.
A genetic predisposition to...
03/18/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
emergency room hospital waiting room reception area
News
Why Aren’t More Emergency Departments Using Medications for OUD Treatment?
03/12/2025
Jolynn Tumolo
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the...
03/12/2025
Psych Congress Network
stethoscope with research images in background medical study clinical trial research
News
Machine Learning Predicts Progression to Schizophrenia Within 5 Years
03/12/2025
Jolynn Tumolo
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used...
03/12/2025
Psych Congress Network
two researchers look at computer screen in lab medical research
News
Continuous D2 Blockade in First-Episode Schizophrenia Does Not Raise Relapse Risk
03/05/2025
Jolynn Tumolo
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous...
03/05/2025
Psych Congress Network
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
A woman lies on the couch holding an ice pack to her head
News
Mild TBI Sustained in Traumatic Context Associated With Worse Long-Term Outcomes
03/03/2025
Jolynn Tumolo
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury...
03/03/2025
Neurology

Quizzes

Death risk increased by how much with a bipolar disorder diagnosis?
Quiz
Death risk increased by how much with a bipolar disorder diagnosis?
02/26/2024
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/26/2024
Psych Congress Network
polygenic risk scores
Quiz
Is there an association between hospitalization frequency and polygenic risk score?
10/06/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
10/06/2022
Psych Congress Network
COVID-19 risk.
Quiz
Antipsychotic Use and COVID-19 Risk in Patients with BD and SMI
06/15/2022
How does antipsychotic use affect COVID-19 risk? Take the quiz now to test your knowledge!
How does antipsychotic use affect COVID-19 risk? Take the quiz now to test your knowledge!
How does antipsychotic use...
06/15/2022
Psych Congress Network
Quiz
Challenges for Patients With Bipolar Disorder
01/11/2022
According to a recent survey, which of the following concerns did patients with bipolar-I disorder report?
According to a recent survey, which of the following concerns did patients with bipolar-I disorder report?
According to a recent survey,...
01/11/2022
Psych Congress Network
Dr Steven Chan
Expert Insights Quiz
Choosing the Right Digital Therapeutic for MDD Treatment
03/18/2025
Steven Chan, MD, MBA; Meagan Thistle
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress...
03/18/2025
Psych Congress Network
Did OUD diagnoses increase or decrease in VHA patients?
Quiz
Did OUD diagnoses increase or decrease in VHA patients?
02/25/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/25/2025
Psych Congress Network
Charles Raison headshot
Expert Insights Quiz
First-Line Treatment Options for Insomnia
02/21/2025
Charles L. Raison, MD
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to...
02/21/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
How many US Psychiatric Hospitals Provided Medications for OUD?
Quiz
How many US psychiatric hospitals provided medications for OUD?
02/06/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/06/2025
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
DSM-5 Quiz: Mood Symptoms in Schizophrenia
02/03/2025
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
02/03/2025
Psych Congress Network
How many people with anxiety disorders receive treatment?
Quiz
How many people with anxiety disorders receive treatment?
01/28/2025
Test your statistical knowledge!
Test your statistical knowledge!
Test your statistical knowledge!
01/28/2025
Psych Congress Network
How can clinicians help patients with ADHD transition from adolescence to adulthood?
Quiz
How can clinicians help patients with ADHD transition from adolescence to adulthood?
01/22/2025
Do you remember this interview with Dr Wilens?
Do you remember this interview with Dr Wilens?
Do you remember this interview...
01/22/2025
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Quiz
Conditions That Mimic ADHD in Pediatric Patients
01/21/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use